Posts by Josephine Galatioto
Immunexpress Announces SeptiCyte® RAPID Testing For Paediatric Sepsis
BRISBANE, Australia, Aug. 24, 2021 /PRNewswire/ — Immunexpress, Pty Ltd, a molecular diagnostic company founded in Brisbane, today announced that the SeptiCyte® RAPID test will be evaluated in the diagnosis of paediatric sepsis in Queensland children. The testing is in part funded through a Federal Government’s Medical Research Future Fund Genomic Health Futures Mission grant for collaborative work between The University of…
Read MoreImmunexpress Presents Data Supporting SeptiCyte® RAPID for COVID-19 Patient Triage as a Late-Breaking Abstract at ECCMID 2021
SEATTLE, July 9, 2021 – Immunexpress, Inc., a molecular diagnostic company focused on improving outcomes for suspected sepsis patients, today announced a late-breaking presentation, titled “Use of SeptiCyte RAPID to assess the risk of ICU admission in COVID-19 patients” (ID#4984), demonstrating the performance of SeptiCyte® RAPID in triaging COVID-19 patients at the 31st European Congress…
Read MoreUse of SeptiCyte® RAPID Assay to Assess the Risk of ICU admission in COVID-19 Patients
ECCMID_P04984_REVIEW_21June2021
Read MoreFinding The Product- Market Fit, with Rollie Carlson Ph.D. CEO of Immunexpress
Gurus, why should you have your engineers and researchers out in the field? How can they get a good product-market fit? What is the NOT INVENTED HERE factor and why should you avoid it? Dr. Carlson discusses this and more. Listen in as he provides further evidence that perfect should not be the enemy of…
Read MoreThe Role of a Host Response Test in Early Identification and Appropriate Intervention for Sepsis
Dr. Roy Davis provides an overview of the current challenges of sepsis diagnosis and management, specifically related to early identification and appropriate intervention. He describes how the host immune response can be leveraged by including a gene expression assay as part of the Sepsis Clinical Toolset. The proposed role for this assay in the clinical…
Read MoreSeptiCyte® RAPID in Sepsis Cases with Malignancies or Treated with Anitneoplastics/Immunosuppressants
A study showing the performance of SeptiCyte RAPID in patients with malignancies and/or on anti-neoplastic or corticosteroid therapies. IMM-009-SCCM-04-01-SC
Read MoreImmunexpress Presents Data Further Demonstrating SeptiCyte® RAPID Performance at the Society of Critical Care Medicine’s 50th Annual Critical Care Congress
Data Demonstrate the Performance of SeptiCyte® RAPID is Unaltered by Patient Malignancy or Treatment with Anti-neoplastics or Immunosuppressants Immunexpress, Inc., a molecular diagnostic company focused on improving outcomes for suspected sepsis patients, today announced a research snapshot presentation of clinical data demonstrating the performance of SeptiCyte® RAPID in adult and pediatric patients with sepsis or systemic…
Read MoreImmunexpress to Present SeptiCyte® RAPID Performance Data at the 50th Critical Care Congress
Immunexpress, Inc., a molecular diagnostic company focused on improving outcomes for suspected sepsis patients, today announced the publication of an abstract for a research snapshot presentation to be presented as part of the Society of Critical Care Medicine’s (SCCM) 50th Annual Critical Care Congress being held virtually Jan. 31 through Feb. 12, 2021. The presentation highlights…
Read MoreA Fully Integrated Diagnostic Test to Discriminate Sepsis from Infection-Negative Systemic Inflammation
Sepsis is a serious medical condition that manifests with a dysregulated immune response to an infection in the bloodstream, and is a major cause of morbidity and mortality worldwide. Many non-infectious conditions can lead to a state of hyper-inflammation known as the systemic inflammatory response syndrome (SIRS), which clinically can look very similar to sepsis.…
Read MoreMolecular Dx Company Biocartis ‘At Inflection Point’ As It Eyes Infectious Disease Market
Executive Summary Belgian developer of cancer diagnostics is building an infectious disease portfolio on the back of its new SARS-CoV-2 test and collaborations with Immunexpress and Endpoint Health.
Read More